PI3Kα/CDK7-IN-1

PI3Kα/CDK7-IN-1 (Compound HY5) inhibits the viability of HCT116, SKOV3 and MCF7 cancer cells carrying PI3Kα mutations, with IC₅₀ values of 360 nM, 490 nM and 820 nM, respectively^[1].
PI3Kα/CDK7-IN-1 reduces the viability of MDA-MB-231, U2OS and NCI-H522 cancer cells, and exhibits stronger activity against NCI-H522 cells overexpressing SLC7A11^[1].
PI3Kα/CDK7-IN-1 (10 μM; 48 h) alters cell cycle progression, induces apoptosis and non-apoptotic cell death, and triggers cellular stress responses in HCT116 cells, as evidenced by increased phosphorylation levels of CDK/MAPK substrates, reduced mitotic index, upregulated levels of activated caspase-3, and formation of pyknotic nuclei^[1].
PI3Kα/CDK7-IN-1 (10 μM; 48 h) induces cellular stress responses in HCT116 cells^[1].
PI3Kα/CDK7-IN-1 (5-10 μM; 24-48 h) reduces the viability of HCT116 cells through both caspase-dependent apoptotic and non-apoptotic mechanisms^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.